Daxor

Daxor Enterprise Value

The Enterprise Value (EV) of Daxor (DXR) as of Oct 17, 2026 is 67.01 M USD. In the previous year, Enterprise Value (EV) was 67.63 M USD — a change of -0.91% (lower).

Enterprise Value

67.01 MUSD

YoY

-0.91%

Last updated:

Enterprise Value (EV) of Daxor is 2025 67.01 M USD. Enterprise Value (EV) of Daxor was 2024 67.63 M USD. It decreases by -0.91% lower compared to the previous year.

The Daxor Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
71.35 M USD
Jan 1, 2019
68.24 M USD
Jan 1, 2020
66.45 M USD
Jan 1, 2021
69.21 M USD
Jan 1, 2022
68.13 M USD
Jan 1, 2023
67.66 M USD
Jan 1, 2024
67.63 M USD
Jan 1, 2025
67.01 M USD
The Daxor Enterprise Value history
YEAREnterprise ValueYoY
67.01 MUSD-0.91%
67.63 MUSD-0.04%
67.66 MUSD-0.70%
68.13 MUSD-1.56%
69.21 MUSD+4.15%
66.45 MUSD-2.62%
68.24 MUSD-4.36%
71.35 MUSD+1.72%
70.15 MUSD+3.89%
67.52 MUSD-1.13%
68.29 MUSD-22.62%
88.26 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Daxor Stock analysis

What does Daxor do? Daxor Corp, listed on the ticker DXR with ISIN US2394671034, is a health care company based in New York City, United States. The company went public on July 25, 1983. Daxor Corp develops and manufactures the BVA-100 blood volume analyzer, a diagnostic instrument cleared by the U.S. Food and Drug Administration (FDA). This device measures human blood volume and provides objective quantification of blood volume status and composition relative to patient-specific norms. The company reports that over 65,000 tests have been conducted at hospital centers across the United States. These tests are associated with improvements in hospital performance metrics for various surgical and medical conditions, including reductions in mortality and readmissions for heart failure and critical care patients. Daxor Corp is engaged in advancing healthcare through blood volume analysis, focusing on optimal fluid management. The company is conducting ongoing clinical trials related to heart failure treatment, supported by the National Institutes of Health (NIH), and is also under contract to develop additional analyzers. The company's website is https://www.daxor.com/. Daxor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Daxor stock

Enterprise Value (EV) of Daxor is 67.01 M USD in 2025.

Enterprise Value (EV) of Daxor changed from 67.63 M USD to 67.01 M USD, representing a -0.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Daxor since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Daxor with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Daxor

All Key Metrics — Daxor